<DOC>
	<DOC>NCT01220869</DOC>
	<brief_summary>A phase III trial investigating the efficacy and safety of degarelix one-month depot in Taiwanese patients with prostate cancer.</brief_summary>
	<brief_title>A Study of Degarelix in Taiwanese Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>20 years or older Has a histological confirmed prostate cancer Has a screening serum testosterone above 1.5 ng/mL Has a Eastern Cooperative Oncology Group (ECOG) score of ≤ 2 Has a screening PSA value of ≥2 ng/mL Has a life expectancy of at least 168 days Current or previous hormone therapy Is currently treated with 5αreductase inhibitor Has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema Is considered to be a candidate for curative therapy, i.e radical prostatectomy or radiotherapy Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin. Has a clinically significant disorder (other than prostate cancer) or any other condition , including alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the trial as judged by the investigator Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>